Muna  Bhanji net worth and biography

Muna Bhanji Biography and Net Worth

Director of Veracyte
Muna Bhanji joined the Veracyte board of directors in 2021. Ms. Bhanji has more than 30 years of strategic and operational experience in the biopharmaceutical industry. She is the Founder and President of Tiba Global Access LLC, an independent senior advisory/consultancy focused on commercialization and market access strategy development, serving the biopharmaceutical industry. She built her career at Merck & Company, Inc., serving most recently as Senior Vice President of Global Market Access & Policy, Global Human Health. In that role, she developed pharmaceutical access and affordability strategies in a highly regulated environment, driving access to medicines in the United States and globally. Ms. Bhanji serves on the boards of biopharmaceutical companies Ardelyx, Intellia and Cytokinetics, Inc., as well as the nonprofit organization Corus International. She previously served on the board of Possible Health, a non-profit with ties to Nepal that delivers affordable and high-quality care to rural and underserved communities, and of the Foundation of Managed Care Pharmacy, which is the research, educational, and philanthropic arm of the Academy of Managed Care Pharmacy. Ms. Bhanji earned her B.S. in Pharmacy from Rutgers University and an M.B.A. from St. Joseph’s University.

What is Muna Bhanji's net worth?

The estimated net worth of Muna Bhanji is at least $944,763.45 as of June 10th, 2024. Ms. Bhanji owns 23,105 shares of Veracyte stock worth more than $944,763 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Bhanji may own. Learn More about Muna Bhanji's net worth.

How do I contact Muna Bhanji?

The corporate mailing address for Ms. Bhanji and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Muna Bhanji's contact information.

Has Muna Bhanji been buying or selling shares of Veracyte?

Muna Bhanji has not been actively trading shares of Veracyte during the last ninety days. Most recently, Muna Bhanji sold 3,870 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.32, for a transaction totalling $78,638.40. Following the completion of the sale, the director now directly owns 23,105 shares of the company's stock, valued at $469,493.60. Learn More on Muna Bhanji's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, insiders at the biotechnology company sold shares 15 times. They sold a total of 77,865 shares worth more than $2,384,720.31. The most recent insider tranaction occured on December, 3rd when insider John Leite sold 1,050 shares worth more than $45,412.50. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 12/3/2024.

Muna Bhanji Insider Trading History at Veracyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2024Sell3,870$20.32$78,638.4023,105View SEC Filing Icon  
5/28/2024Sell1,539$21.00$32,319.0026,975View SEC Filing Icon  
6/16/2023Sell5,893$26.44$155,810.9228,514View SEC Filing Icon  
5/30/2023Sell1,539$25.91$39,875.4924,733View SEC Filing Icon  
See Full Table

Muna Bhanji Buying and Selling Activity at Veracyte

This chart shows Muna Bhanji's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $40.89
Low: $38.44
High: $41.38

50 Day Range

MA: $38.50
Low: $32.45
High: $44.40

2 Week Range

Now: $40.89
Low: $18.61
High: $46.00

Volume

2,010,201 shs

Average Volume

773,634 shs

Market Capitalization

$3.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69